Citadel Advisors
ACXP icon

Citadel Advisors’s Acurx Pharmaceuticals ACXP Stock Holding History

Citadel Advisors’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,845
Closed -$29.1K – 12639
2025
Q2 		$29.1K Buy
+2,845
New +$22.9K ﹤0.01% 11995
2025
Q1 		– Sell
-200
Closed -$3.26K – 14376
2024
Q4 		$3.26K Sell
200
-285
-59% -$8.58K ﹤0.01% 14008
2024
Q3 		$18.4K Sell
485
-430
-47% -$18.2K ﹤0.01% 12843
2024
Q2 		$41.2K Sell
915
-775
-46% -$34.1K ﹤0.01% 11962
2024
Q1 		$82.8K Buy
1,690
+145
+9% +$9.43K ﹤0.01% 11614
2023
Q4 		$118K Buy
+1,545
New +$117K ﹤0.01% 10718

Other funds holding ACXP

PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
CPG
Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return
GWSG
GPS Wealth Strategies Group Centennial, Colorado $117M AUM 24.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Citadel Advisors's ACXP Position: Q3 2024 in Review

Citadel Advisors sold out of Acurx Pharmaceuticals (ACXP) in Q3 2024, closing a stake of 3 shares — an estimated $127 sold.

Citadel Advisors first reported a position in ACXP in Q3 2023 and held it in 3 quarters. The position peaked at $52.5K in Q4 2023. 22 funds tracked by Wall St. Rank hold ACXP as of Q3 2024.

  • Citadel Advisors reported no remaining Acurx Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 3 Acurx Pharmaceuticals shares in Q3 2024, an estimated $127.
  • Citadel Advisors first reported a position in Acurx Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Citadel Advisors's Acurx Pharmaceuticals position peaked at $52.5K in Q4 2023.
  • 22 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.